📈 The Tape Reader

Tuesday, August 18, 2026

12 stories · Standard format

Generated with AI from public sources. Verify before relying on for decisions.

🎧 Listen to this briefing or subscribe as a podcast →

Earnings surprises and clinical trial readouts are splintering the tape today, with AI optical suppliers extending their recent breakouts alongside aggressive repositioning in the retinal drug market.

Episodic Pivots

AXT Inc. (AXTI) Rips 14% on Blowout Q2, Q3 Boost, and Lumentum Supply Deal

Extending the momentum from the blowout Q2 earnings and Lumentum supply agreement we tracked earlier this month, AXT Inc. shares ripped another 14% on Monday. The market continues to bid up the optical supplier on its record $30.7M in indium phosphide sales and a confirmed backlog that now sits above $100M.

AXTI provides a textbook episodic pivot setup: a massive beat-and-raise powered by a verified structural shift into AI optical networking. The long-term Lumentum lock-in validates multi-year demand visibility. Watch for intraday flag consolidation above Monday's breakout level for high-volume swing continuation.

Verified across 2 sources: Timothy Sykes News · StocksToTrade

Semtech (SMTC) Climbs 10% on $62M Divestiture to Focus Pure-Play AI Networking

Semtech Corporation surged 10.33% to close near $154.86 on Monday after entering a definitive agreement to sell its non-core cellular module business to Compal Electronics for $62 million in cash. The cash proceeds sharpen management's focus on high-margin AI data center optical networking and LoRa/IoT connectivity ahead of its upcoming Q2 earnings print.

Streamlining the corporate structure into a pure-play AI networking vehicle provides a fundamental inflection point. The cash injection eliminates balance sheet drag ahead of earnings, establishing a high-volume base breakout structure with clear invalidation at Monday's low.

Verified across 1 sources: Timothy Sykes News

Mativ Holdings (MATV) Surges 11% Premarket on Blowout Q2 Earnings Surprises

Mativ Holdings gapped up 11% on Monday after reporting Q2 EPS of $0.50 against $0.28 consensus estimates. The earnings beat was accompanied by expanding gross margins, pricing power in specialty materials, and accelerated debt reduction.

A clean beat-and-raise episodic pivot in an under-the-radar industrial name. The 78% EPS surprise off a multi-month base creates a clean high-volume gap setup with defined risk at the opening range low.

Verified across 1 sources: Investing.com

Momentum & Breakouts

IES Holdings (IESC) Announces 2-for-1 Stock Split and $650M DBM Global Acquisition

Extending the post-earnings gap consolidation tracked last week, IES Holdings announced a 2-for-1 stock split effective August 24, paired with a $650 million acquisition of structural steel firm DBM Global from Innovate Corp. The transaction significantly expands IESC's data center construction capacity.

Stock splits combined with strategic, accretive M&A in data center infrastructure provide strong liquidity and growth tailwinds. The announcement helps resolve IESC's multi-day post-earnings tight flag to the upside on expanding institutional volume.

Verified across 1 sources: Financial Modeling Prep

Catalyst-Driven News

EyePoint Pharmaceuticals (EYPT) Collapses 70% as Wet AMD Trial Misses Endpoint

EyePoint Pharmaceuticals dropped 70% on Monday after its Phase 3 trial for sustained-release wet AMD asset Duravyu failed to meet its primary visual acuity endpoint due to unexpected vision loss in a trial cohort. Management attempted to defend the asset via ad hoc sub-group analysis, but the market heavily penalized the stock.

A catastrophic binary trial failure that completely unwinds EYPT's core commercial thesis against Regeneron's Eylea. For swing traders, the wash-out creates a toxic holding environment, taking long setups completely off the table while opening aggressive short-side continuation setup windows on any weak intraday bounces.

Verified across 1 sources: Fierce Pharma

Ocular Therapeutix (OCUL) Jumps 7.5% in Sympathy Flow Following Rival Miss

Ocular Therapeutix stock jumped 7.5% on Monday as capital immediately rotated into the ticker following rival EyePoint Pharmaceuticals' Phase 3 Duravyu trial failure. Market participants re-priced OCUL's competing AXPAXLI program to reflect reduced competitive headwinds in the long-acting retinal drug market.

Classic second-order sympathy play where a primary competitor's clinical disaster instantly expands the TAM and valuation multiple for the surviving market peer. Monitor relative volume confirmation and flag setups near multi-week resistance as institutional desks re-weight retinal pipeline baskets.

Verified across 1 sources: Prism Marketview

Argenx (ARGX) Soars 16% as Vyvgart Wins Phase 3 Study in Autoimmune Myositis

Argenx shares jumped over 16% on Monday after reporting that subcutaneous efgartigimod (Vyvgart Hytrulo) achieved its primary endpoint in the Phase 2/3 Alkivia study for autoimmune myositis. The company plans to submit a supplemental BLA to the FDA, unlocking a significant new patient population.

Expanding Vyvgart's label into myositis solidifies Argenx's dominant commercial franchise in FcRn blockers. The Phase 3 win delivers a gap-and-go breakout out of a multi-week consolidation range on heavy institutional volume.

Verified across 2 sources: Longbridge · Fierce Pharma

Analyst Actions

Micron (MU) Reclaims $1,000 Level on New Street Upgrade to $1,250 Target

Adding to the momentum from the 2027 HBM capacity lockups we noted earlier today, Micron Technology drew fresh institutional flow as New Street upgraded the stock to Buy with a $1,250 price target. The desk argued that structural HBM4 demand for Nvidia's Vera Rubin platform has decoupled Micron from traditional memory boom-and-bust cycles.

A high-conviction tier-1 desk upgrade asserting a structural cycle break provides strong fundamental backing for high-beta continuation. Watch for holding action above the $1,000 psychological pivot zone as institutional desks re-rate memory target multiples.

Verified across 4 sources: Defense World · TIKR · Trading Strategy Guides · FX Leaders

Rothschild Upgrades Apple (AAPL) to Buy with $400 Target on Foldable Cycle

Countering recent sell-side downgrades from Jefferies, Rothschild & Co Redburn upgraded Apple to Buy on Monday and raised its price target from $260 to $400. The firm cited supply-chain checks pointing toward a September foldable iPhone launch and potential margin expansion via open-source AI integration.

A sharp target delta from $260 to $400 on a mega-cap tech anchor directly challenges recent bearish supply-chain narratives. Look for opening drive relative strength as institutional flow absorbs recent downgrade overhead.

Verified across 2 sources: TipRanks · Invezz

Parabolic Long/Short

Sandisk (SNDK) Extends Parabolic Expansion to $1,786 on AI Memory Guidance

Sandisk extended its multi-day parabolic expansion to $1,786.85 on Monday, logging a 35% weekly run. The advance follows management's upbeat Investor Day targets projecting mid-to-high-teens revenue growth through 2030, supported by a 9th-generation high-performance flash technology launch targeting AI infrastructure storage.

SNDK displays extreme parabolic momentum with RSI levels stretched well into overbought territory. While structural AI storage demand remains intact, traders should watch for signs of climactic intraday blow-off volume near $1,943 resistance for potential mean-reversion short or flush-and-rebound setups.

Verified across 2 sources: StocksToTrade News · FX Leaders

Nike (NKE) Flushes 3.1% to 52-Week Lows on China Drag and Dividend Scrutiny

Nike shares dropped 3.1% on Monday to break key structural support and hit a fresh 52-week low of $39.47. The relentless markdown is driven by persistent sales contraction in Greater China and sell-side desk notes highlighting elevated dividend payout ratios.

NKE presents a classic short-side trend continuation setup that is approaching potential exhaustion territory. Active traders should monitor for washout panic flushes on high relative volume to signal a tactical mean-reversion bounce setup.

Verified across 1 sources: TS2 Tech

Macro Catalysts

WTI Oil Breaks $84.50 on Ceasefire Friction, Pressuring Macro Fed Rate Cut Outlook

Reversing the crude oil plunge we tracked earlier this month amid US-Iran de-escalation hopes, WTI surged back past $84.50 per barrel on Monday following the breakdown of diplomatic frameworks under the Islamabad memorandum. The energy spike re-injects headline supply risk into inflation metrics, pushing CME FedWatch September rate-cut odds down to 31% ahead of Wednesday's July FOMC minutes release.

Resurgent crude oil pricing complicates the Fed's dovish pivot, threatening to put upward pressure on Treasury yields and cap index upside. Equity traders must watch energy-sensitive sectors and yield-proxy equities for intraday macro drag.

Verified across 3 sources: StockWireX · FinanceFeeds · Pip Theory


The Big Picture

Indium Phosphide and Memory Lead AI Hardware Expansion Institutional order flow is heavily concentrating in core connectivity and memory components (AXT, Micron, Sandisk) backed by multi-year off-take agreements with optical module heavyweights.

Binary Trial Failures Drive Immediate Sympathy Shifts Severe clinical misses like EyePoint's wet AMD trial are triggering instant capital reallocation into surviving peer assets like Ocular Therapeutix.

Data Center Restructuring Triggers Episodic Re-Ratings Equities executing strategic carve-outs (Semtech) or debt-clearing acquisitions (IES Holdings) are breaking multi-month bases on expanding relative volume.

Tier-1 Sell-Side Desks Re-Anchor High-Beta Targets Aggressive target hikes and initiations from desks like New Street, Rothschild, and Piper Sandler are triggering immediate gap-and-go momentum setups in established leaders.

Geopolitical Energy Spikes Re-Inject Volatility into Macro Rates WTI crude pushing past $84.50 following Middle East ceasefire friction is complicating Fed policy expectations heading into the July FOMC minutes.

What to Expect

2026-08-19 FOMC July Meeting Minutes release and Wolfspeed (WOLF) Q4 FY26 earnings print
2026-08-24 IES Holdings (IESC) 2-for-1 stock split effective date
2026-09-30 Scholar Rock (SRRK) FDA action date for apitegromab in SMA

Every story, researched.

Every story verified across multiple sources before publication.

🔍

Scanned

Across multiple search engines and news databases

562
📖

Read in full

Every article opened, read, and evaluated

92

Published today

Ranked by importance and verified across sources

12

— The Tape Reader

🎙 Listen as a podcast

Subscribe in your favorite podcast app to get each new briefing delivered automatically as audio.

Apple Podcasts
Library tab → ••• menu → Follow a Show by URL → paste
Overcast
+ button → Add URL → paste
Pocket Casts
Search bar → paste URL
Castro, AntennaPod, Podcast Addict, Castbox, Podverse, Fountain
Look for Add by URL or paste into search

Spotify isn’t supported yet — it only lists shows from its own directory. Let us know if you need it there.